A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, Peter P. Lee, Samir N. Khleif, Magdalena Thurin, Giorgio Trinchieri, Ena Wang, Jon Wigginton, Damien Chaussabel, George Coukos, Madhav Dhodapkar, Leif Håkansson, Sylvia Janetzki, Thomas O. Kleen, John M. Kirkwood, Cristina Maccalli, Holden Maecker, Michele Maio, Anatoli MalyguineGiuseppe Masucci, A. Karolina Palucka, Douglas M. Potter, Antoni Ribas, Licia Rivoltini, Dolores Schendel, Barbara Seliger, Senthamil Selvan, Craig L. Slingluff, David F. Stroncek, Howard Streicher, Xifeng Wu, Benjamin Zeskind, Yingdong Zhao, Mai Britt Zocca, Heinz Zwierzina, Francesco M. Marincola

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.

Original languageEnglish (US)
Article number81
JournalJournal of Translational Medicine
Volume6
DOIs
StatePublished - Dec 23 2008

Fingerprint

Biological Therapy
Biomarkers
United States Food and Drug Administration
Immunotherapy
Tumors
Assays
Feedback
Monitoring
Advisory Committees
Neoplasms
Practice Guidelines
Immunologic Monitoring
Education

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Butterfield, L. H., Disis, M. L., Fox, B. A., Lee, P. P., Khleif, S. N., Thurin, M., ... Marincola, F. M. (2008). A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 6, [81]. https://doi.org/10.1186/1479-5876-6-81

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". / Butterfield, Lisa H.; Disis, Mary L.; Fox, Bernard A.; Lee, Peter P.; Khleif, Samir N.; Thurin, Magdalena; Trinchieri, Giorgio; Wang, Ena; Wigginton, Jon; Chaussabel, Damien; Coukos, George; Dhodapkar, Madhav; Håkansson, Leif; Janetzki, Sylvia; Kleen, Thomas O.; Kirkwood, John M.; Maccalli, Cristina; Maecker, Holden; Maio, Michele; Malyguine, Anatoli; Masucci, Giuseppe; Palucka, A. Karolina; Potter, Douglas M.; Ribas, Antoni; Rivoltini, Licia; Schendel, Dolores; Seliger, Barbara; Selvan, Senthamil; Slingluff, Craig L.; Stroncek, David F.; Streicher, Howard; Wu, Xifeng; Zeskind, Benjamin; Zhao, Yingdong; Zocca, Mai Britt; Zwierzina, Heinz; Marincola, Francesco M.

In: Journal of Translational Medicine, Vol. 6, 81, 23.12.2008.

Research output: Contribution to journalArticle

Butterfield, LH, Disis, ML, Fox, BA, Lee, PP, Khleif, SN, Thurin, M, Trinchieri, G, Wang, E, Wigginton, J, Chaussabel, D, Coukos, G, Dhodapkar, M, Håkansson, L, Janetzki, S, Kleen, TO, Kirkwood, JM, Maccalli, C, Maecker, H, Maio, M, Malyguine, A, Masucci, G, Palucka, AK, Potter, DM, Ribas, A, Rivoltini, L, Schendel, D, Seliger, B, Selvan, S, Slingluff, CL, Stroncek, DF, Streicher, H, Wu, X, Zeskind, B, Zhao, Y, Zocca, MB, Zwierzina, H & Marincola, FM 2008, 'A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"', Journal of Translational Medicine, vol. 6, 81. https://doi.org/10.1186/1479-5876-6-81
Butterfield, Lisa H. ; Disis, Mary L. ; Fox, Bernard A. ; Lee, Peter P. ; Khleif, Samir N. ; Thurin, Magdalena ; Trinchieri, Giorgio ; Wang, Ena ; Wigginton, Jon ; Chaussabel, Damien ; Coukos, George ; Dhodapkar, Madhav ; Håkansson, Leif ; Janetzki, Sylvia ; Kleen, Thomas O. ; Kirkwood, John M. ; Maccalli, Cristina ; Maecker, Holden ; Maio, Michele ; Malyguine, Anatoli ; Masucci, Giuseppe ; Palucka, A. Karolina ; Potter, Douglas M. ; Ribas, Antoni ; Rivoltini, Licia ; Schendel, Dolores ; Seliger, Barbara ; Selvan, Senthamil ; Slingluff, Craig L. ; Stroncek, David F. ; Streicher, Howard ; Wu, Xifeng ; Zeskind, Benjamin ; Zhao, Yingdong ; Zocca, Mai Britt ; Zwierzina, Heinz ; Marincola, Francesco M. / A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". In: Journal of Translational Medicine. 2008 ; Vol. 6.
@article{b72c21660a1441a3bbac586ee0397ffa,
title = "A systematic approach to biomarker discovery; Preamble to {"}the iSBTc-FDA taskforce on immunotherapy biomarkers{"}",
abstract = "The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.",
author = "Butterfield, {Lisa H.} and Disis, {Mary L.} and Fox, {Bernard A.} and Lee, {Peter P.} and Khleif, {Samir N.} and Magdalena Thurin and Giorgio Trinchieri and Ena Wang and Jon Wigginton and Damien Chaussabel and George Coukos and Madhav Dhodapkar and Leif H{\aa}kansson and Sylvia Janetzki and Kleen, {Thomas O.} and Kirkwood, {John M.} and Cristina Maccalli and Holden Maecker and Michele Maio and Anatoli Malyguine and Giuseppe Masucci and Palucka, {A. Karolina} and Potter, {Douglas M.} and Antoni Ribas and Licia Rivoltini and Dolores Schendel and Barbara Seliger and Senthamil Selvan and Slingluff, {Craig L.} and Stroncek, {David F.} and Howard Streicher and Xifeng Wu and Benjamin Zeskind and Yingdong Zhao and Zocca, {Mai Britt} and Heinz Zwierzina and Marincola, {Francesco M.}",
year = "2008",
month = "12",
day = "23",
doi = "10.1186/1479-5876-6-81",
language = "English (US)",
volume = "6",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

AU - Butterfield, Lisa H.

AU - Disis, Mary L.

AU - Fox, Bernard A.

AU - Lee, Peter P.

AU - Khleif, Samir N.

AU - Thurin, Magdalena

AU - Trinchieri, Giorgio

AU - Wang, Ena

AU - Wigginton, Jon

AU - Chaussabel, Damien

AU - Coukos, George

AU - Dhodapkar, Madhav

AU - Håkansson, Leif

AU - Janetzki, Sylvia

AU - Kleen, Thomas O.

AU - Kirkwood, John M.

AU - Maccalli, Cristina

AU - Maecker, Holden

AU - Maio, Michele

AU - Malyguine, Anatoli

AU - Masucci, Giuseppe

AU - Palucka, A. Karolina

AU - Potter, Douglas M.

AU - Ribas, Antoni

AU - Rivoltini, Licia

AU - Schendel, Dolores

AU - Seliger, Barbara

AU - Selvan, Senthamil

AU - Slingluff, Craig L.

AU - Stroncek, David F.

AU - Streicher, Howard

AU - Wu, Xifeng

AU - Zeskind, Benjamin

AU - Zhao, Yingdong

AU - Zocca, Mai Britt

AU - Zwierzina, Heinz

AU - Marincola, Francesco M.

PY - 2008/12/23

Y1 - 2008/12/23

N2 - The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.

AB - The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for the identification of relevant parameters to assist clinical and basic scientists who study the natural course of host/tumor interactions or their response to immune manipulation. The task force has two primary goals: 1) identify best practices of standardized and validated immune monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for the identification of novel biomarkers that may enhance our understating of principles governing human cancer immune biology and, consequently, implement their clinical application. Two working groups were created that will report the developed best practices at an NCI/FDA/iSBTc sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the Fall of 2009. This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document.

UR - http://www.scopus.com/inward/record.url?scp=59349089815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59349089815&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-6-81

DO - 10.1186/1479-5876-6-81

M3 - Article

C2 - 19105846

AN - SCOPUS:59349089815

VL - 6

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 81

ER -